Want to join the conversation?
$AMGN's research and development expenses for 1Q16 declined by 2% from last year. This was driven by decreased costs associated with its later stage clinical programs support of $264MM, offset by increased costs in marketed products support of $242MM.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.